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Introduction
Smooth muscle cell proliferation and extracellular matrix
(ECM) synthesis/turnover are thought to play an impor-
tant role in vessel wall repair after vascular injury.
Recently, we identified the cysteine-rich-protein-2 (CRP2)
as novel and specific molecular effector of the NO/cGMP/
cGMP-dependent-protein-kinase-I (PKG) signaling in vas-
cular smooth muscle. To elucidate whether CRP2 contrib-
utes to the postulated pro-proliferative/proatherogenic
effect of PKG, we established a CRP2-deficient mouse line
by targeted deletion of the exons 2–7 in the CRP2-gene.
With the simultaneous development of a novel ECM-spe-
cific MR contrast agent (BMS753951) non-invasive assess-
ment of changes in remodeling of the injured mouse
carotid wall has become feasible.
Purpose
In this study we investigated whether the use of an elastin-
binding contrast agent would allow the detection of vas-
cular remodeling in a mouse model of carotid artery
injury and whether it would facilitate the detection of
impaired ECM formation in CRP2-/- mice.
Methods
A carotid artery injury model was performed in 8 wild-
type and 8 CRP2-deficient (CRP2-/-) mice; the right
carotid artery wall was damaged, while the left served as
control. Two month after surgical intervention, MRI of the
carotid vessel walls was performed in a 1.5 T Philips
Achieva clinical MR scanner using a single loop small ani-
mal coil, a dedicated cardiac software package (R1.2.2)
and a clinical gradient system (30 mT/m, 150 mT/m/ms).
Time-of-flight angiography of the carotid arteries was per-
formed for visualization of the injured vessel segment and
for subsequent planning of the vessel wall scans. Imaging
parameters included TR = 43, TE = 8.1, flip angel = 60°,
spatial resolution = 0.2 × 0.2 × 0.5 mm. For assessment of
ECM remodeling, an inversion recovery vessel wall
sequence was performed approximately 45–60 minutes
post injection of 0.1 mmol/kg of BMS753951 (Bristol-
Myer-Squibb/Billerica/MA), a novel elastin-binding Gd-
based contrast agent. Imaging parameters included TR =
44, TE = 11, flip-angel = 30°, spatial resolution = 0.1 × 0.1
× 0.5 mm, 22 lines per RR-interval, inversion time approx.
250 ms. Signal-to-noise and contrast-to-noise-ratio (SNR,
CNR) of the injured vessel wall was determined by man-
ual segmentation of the visually apparent signal of the
contrast agent below the carotid bifurcation. Noise was
determined within a region of interest drawn outside the
animal.
To verify our MR data, we performed histological elastic-
staining in a 10 μm-whole-neck paraffin-slice using the
common Elastica-Van-Gieson-method.
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SNR and CNR of the injured right compared to the non
injured left carotid artery was significantly increased (p <
0.001) both in wild-type (SNR: 12.9 ± 2.2 vs. 5.8 ± 1.9;
CNR: 10.8 ± 1.8 vs. 4.3 ± 2.3; Figure 1A) and in CRP2-/-
mice (SNR: 9.4 ± 1.6 vs. 6.4 ± 2.1; CNR: 7.9 ± 1.8 vs. 4.9
± 1.7; Figure 1B). More interestingly, SNR (12.9 ± 2.2 vs.
9.4 ± 1.6) and CNR (10.8 ± 1.8 vs. 7.9 ± 1.8) of the injured
right carotid artery of CRP2-/- mice was significantly
decreased when compared to control animals (p < 0.05)
(Figure 2). No significant difference was found between
non-injured carotid arteries of both genotypes (SNR: p =
0.35, CNR: p = 0.36).
In both genotypes, the carotid injury per se was confirmed
in 10 μm-whole-neck paraffin sections stained with Elas-
tica-Van-Gieson (Figure 3). Preliminary evaluation of the
carotid wall thickening seem to confirm our MRI findings
and suggests that targeted deletion of CRP2 in mice might
lead to a reduced vessel wall thickening and thus to a
reduced restenosis after vascular injury. However, the
semi-quantitative analysis of carotid vessel wall thicken-
ing in both genotypes is currently still under investigation.
Conclusion
In this study, we demonstrate the successful use of molec-
ular MRI for the non-invasive assessment of alterations in
the vessel wall after vascular injury in a mouse model of
impaired smooth muscle cell proliferation and ECM for-
mation. The use of BMS753951 allows the differentiation
of molecular alterations in the injured and non-injured
vessel wall, as well as between wild-type and CRP2-/- mice
with regard to elastin formation after vascular injury.
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